Some probe development as well as preclinical investigations involving ‘cold’ (Liolios et al., 2012) or radiolabeled 64Cu-bombesin conjugates have also been reported (Hueting at al, 2010), including assays in vitro and in vivo for radiopharmacological evaluation (Bergmann et al., 2013) Moreover, combined radiolabelled targeting-peptide compounds have also been studied as therapeutic agents which can interfere with cellular growth in prostate cancer (Cui et al., 2013; Morgat et al., 2014; Moreno et al., 2016). This evidence concerns the gene GRP and Familial prostate cancer.